血小板活化因子对大鼠黄体细胞孕酮分泌及血管内皮生长因子表达的作用

本文旨在研究血小板活化因子(platelet-activating factor,PAF)对大鼠黄体细胞孕酮分泌及血管内皮生长因子(vascularendothelial growth factor,VEGF)mRNA表达的作用.将未成年(25～28 d)Sprague-Dawley雌性大鼠颈部皮下注射50 IU孕马血清促性腺激素(pregnant mare serum gonadotrophin,PMSG),48 h后注射25 IU人绒毛膜促性腺激素(human chorionicgonadotrophin.hCG)诱导卵泡发育和黄体生成,第6天(hCG注射日为第1天)收集卵巢黄体细胞,体外培养24 h后,不加或加入不同剂量(0.1 μg/mL、1 μg/mL、10 μg/mL)PAF,37℃、5%CO2培养箱内培养24 h.用放射免疫方法测定培养液中孕酮的含量,流式细胞仪和RT-PCR方法检测黄体细胞凋亡以及VEGF mRNA的表达.结果显示,PAF促进黄体细胞孕酮分泌,1 μg/mL PAF作用最强(P<0.05);PAF促进黄体细胞凋亡无明显剂量依赖性,但10 μg/mL PAF显著促进大鼠黄体细胞凋亡(P<0.05):PAF刺激黄体细胞VEGF mRNA表达,1 μg/mL PAF效果最显著(P<0.01).结果提示,PAF可通过调节黄体细胞孕酮的分泌和VEGF mRNA的表达来促进黄体形成.     

血小板活化因子对大鼠卵巢颗粒细胞垂体腺苷酸环化酶激活肽mRNA表达的影响及调节机制

目的：探讨血小板活化因子（PAF）对大鼠卵巢颗粒细胞垂体腺苷酸环化酶激活肽（PACAP）mRNA表达的影响及其可能调节机制,旨在寻找PAF在卵巢中的作用靶点。方法：原代培养卵巢颗粒细胞,用放射免疫分析（RIA）及逆转录．聚合酶链反应（RT-PCR）方法检测颗粒细胞雌二醇分泌情况及其PACAP mRNA表达变化．结果：PAF对PACAP mRNA表达无明显影响,但与hCG共同作用可促进PACAP mRNA的表达：Forkolin可使PACAP mRNA表达升高。结论：PAF可通过对hCG的允许作用间接促进大鼠卵巢颗粒细胞PACAP mRNA表达,hCG的促进作用可能是通过cAMP—PKA途径介导的。     

心房钠尿肽(ANP)对大鼠卵巢细胞生成雌激素与孕激素的影响

应用大鼠卵巢黄体细胞、颗粒细胞培养以及放射免疫分析法,观察了α型心房钠尿肽(α-ANP)对性甾体激素孕酮(P)和雌二醇(E_2)分泌的影响,结果发现,0.1—10ng/ml 浓度的α-ANP 促进离体培养的大鼠黄体细胞分泌孕酮,并呈量效关系。α-ANP 也促进大鼠卵泡颗粒细胞分泌孕酮,但对分泌雌二醇没有影响。说明α-ANP 也影响卵巢分泌功能。     

阿片肽类物质对大鼠黄体细胞孕酮生成的影响

本文观察了外源性阿片肽对大鼠离体黄体细胞孕酮生成的影响,结果表明:β-内啡肽以剂量-反应依赖方式促进黄体细胞孕酮生成,有效浓度范围是10~(-8)-10~(-6) mol/L;强啡肽仅在浓度为10~(-6)mol/L时才显示刺激孕酮生成的作用;而甲硫-脑啡肽无明显作用。μ-阿片受体激动剂DAGO和乙基吗啡也能明显促进孕酮的生成。纳洛酮可完全阻断β-内啡肽,DAGO和乙基吗啡的作用。由于大鼠血液中β-内啡肽含量较低,而卵巢局部具有较高浓度的β-内啡肽。因此,我们认为,β-内啡肽可能在卵巢局部参与黄体细胞孕酮生成的调节,是卵巢内促黄体因子之一,这种作用可能是由μ-型阿片受体介导的。     

二十一种氨基酸对hCG致大鼠黄体细胞孕酮生成作用的影响

本文选用PMSG-hCG预处理的未成年雌性大鼠卵巢黄体经DNA酶-胶原酶消化后,制成黄体细胞悬浮液。在黄体细胞悬浮液的培养管内,加入hCG100mIU/ml 100μl,同时加入三种浓度(0.02,0.2,2mmol/L)的二十一种氨基酸,充入95％O_2+5％CO_2,37℃孵育1.5h,用放射免疫分析方法测孕酮含量。结果表明:二十一种氨基酸中,只有酪氨酸、苏氨酸、丝氨酸可对抗hCG致孕酮生成作用。这三种氨基酸在结构上均具有羟基,都是蛋白质磷酸化的位点,据此推测:这三种氨基酸抗hCG致孕酮生成作用可能与干扰蛋白激酶的磷酸化有关。     

微囊化新生大鼠卵巢组织体外及异体移植

为探讨海藻酸钠-聚左赖氨酸-海藻酸钠(APA)微囊化新生大鼠卵巢组织用于治疗实验性卵巢功能丧失大鼠的可行性,应用高压静电法,用海藻酸钠-聚左赖氨酸-海藻酸钠(APA)生物膜包裹新生大鼠卵巢组织,体外培养微囊,用免疫化学分析法检测雌二醇(E2)、孕酮(P)分泌情况,透射电镜观察卵巢组织形态,并将微囊移植到去势大鼠(切除双侧卵巢的雌性大鼠)腹腔中,检测大鼠血清中雌、孕激素变化情况,同时用阴道涂片观察大鼠动情周期恢复情况,并在不同时间回收观察微囊。结果显示在相同条件下制得的微囊粒径均匀、表面光滑;体外培养条件下持续分泌E2、P;卵巢组织中颗粒细胞发育成为粒性黄体细胞;大鼠腹腔移植微囊后无异常,E2、P水平上升,动情周期未恢复;回收的微囊大部分形态完整。提示用高压静电法制备的APA微囊化新生大鼠卵巢组织能持续稳定释放E2、P,明显改善大鼠卵巢功能,在大鼠体内有良好的生物相容性。     

大鼠黄体细胞酪氨酸含量及hCG,cAMP和孕酮对含量的影响

经PMSG-hCG处理的未成年雌性大鼠卵巢,用胶原酶-DNA酶溶液消化,制成黄体细胞悬浮液。预培育1h后,加入不同浓度的hCG、cAMP及孕酮;并在加入hCG(10mIU/ml)、cAMP(2.5mmol/L)或孕酮(1nmol/L)的同时分别加入苯丙氨酸或放线菌酮,再培育1.5h,取细胞悬浮液400μl,用薄层层析扫描技术测其酪氨酸含量。结果:黄体细胞内有一定量内源酪氨酸,hCG,cAMP和孕酮均可明显促进酪氨酸的释放(P<0.05).苯丙氨酸对酪氨酸的含量无影响。酪氨酸释放也不依赖蛋白质合成过程。     

Slit/Robo通路参与调控小鼠黄体细胞凋亡

本文旨在研究Slit/Robo家族成员在小鼠卵巢组织中的表达及其功能。用real-time PCR检测Slit/Robo家族成员在小鼠卵巢中的mRNA表达丰度,用免疫组织化学方法检测Slit2/Robo1在卵巢组织中的定位,用real-time PCR和免疫组织化学方法检测Slit2/Robo1在不同时期黄体组织中表达的变化,并用Slit/Robo信号通路的阻断剂ROBO1/Fc chimera在体外研究其在小鼠黄体组织中的功能。结果显示,在Slit/Robo家族成员中,配体Slit2和受体Robo1在小鼠卵巢组织中的表达丰度最高,Slit2和Robo1表达定位于小鼠的黄体细胞。与发情前期卵巢相比,间情期卵巢组织中Slit2和Robo1的mRNA表达水平均显著上调(P 0.01, P 0.001)。与妊娠黄体相比,晚期黄体Slit2和Robo1 mRNA表达水平均显著上调。阻断Slit/Robo信号通路后,晚期黄体细胞的凋亡率显著下降(P 0.05)。以上结果提示,Slit/Robo家族成员主要表达于晚期黄体组织,并参与调控黄体细胞的凋亡过程。     

原癌基因c-erbB_2在原始卵泡启动生长中的作用

目的:探讨原癌基因c-erbB2在原始卵泡启动生长中表达变化及可能的作用。方法:选用2日龄SD大鼠卵巢在Waymouth培养体系中进行体外培养,用原位杂交、RT-PCR和免疫组化方法检测c-erbB2mRNA和蛋白在原始卵泡启动生长中及在表皮生长因子(EGF)作用下的表达情况,用Westernblot方法同步测定卵泡活化生长的重要标志物——增殖细胞核抗原(PCNA)和磷酸化细胞外信号调节激酶1/2(p-ERK1/2)的表达情况,并分析p-ERK1/2与c-erbB2mRNA表达变化的相关关系。结果:伴随原始卵泡启动生长过程,PCNA表达逐渐增加,EGF能促进原始卵泡的增殖和分化;原始卵泡中有c-erbB2mRNA及蛋白的表达,且随原始卵泡的启动生长及在EGF作用下表达增强;RT-PCR结果显示,c-erbB2mRNA表达在2日龄大鼠卵巢培养8d后与培养0d相比显著增加(0.297±0.018vs0.178±0.011,P0.05),并在EGF作用下进一步增强;p-ERK1/2含量的变化与c-erbB2mRNA表达的变化呈显著的正相关关系(rs=0.900,P0.05)。结论:c-erbB2在原始卵泡启动生长中起重要促进作用,并为介导EGF促进原始卵泡启动生长的关键信号分子;ERK-MAPK信号通路可能在介导c-erbB2调控原始卵泡生长中起作用。     

GABA影响大鼠卵巢黄体细胞孕酮的生成

实验用离体培养方法观察ＧＡＢＡ对大鼠黄体细胞孕酮及羟自由基（．ＯＨ）生成的影响。结果表明：ＧＡＢＡ抑制黄体细胞孕酮的生成,同时也促进黄体细胞．ＯＨ的生成。ＧＡＢＡ对孕酮的抑制作用可能与腺苷酸环化酶系统及ＧＡＢＡＡ型受体有关,而与蛋白质合成无关。     

Detection of steroidogenic acute regulatory protein in equine ovaries

A steroidogenic acute regulatory (StAR) protein has been identified in several species as a probable important rate-limiting step in steroidogenesis. This protein is believed to be responsible for transporting cholesterol from the outer to the inner mitochondrial membrane. It is known that equine chorionic gonadotrophin (eCG) stimulates steroidogenesis in the corpora lutea of early pregnant mares and that eCG also upregulates StAR mRNA in bovine ovaries. In the present study, ovarian tissue from cyclic and early pregnant mares was immunostained to detect the distribution of the StAR protein. Western blot analysis was performed, followed by phosphor imaging to establish whether the onset of eCG secretion in pregnancy was associated with increased expression of the StAR protein. Immunostaining for StAR was confined to the theca interna of growing and preovulatory follicles, but 24 h after treatment with hCG, some granulosa cells were positively stained. Positive staining was confined to the large luteal cells of the equine corpus luteum. There was no difference in the distribution of immunostaining before or after onset of eCG secretion in pregnant mares, but increased amounts of StAR were detected in corpora lutea from mares at day 40 or day 41 of pregnancy compared with non-pregnant mares and mares at days 20-30 of pregnancy.     

Demonstration of luteinizing hormone/human chorionic gonadotrophin receptor-binding inhibitor in aqueous extracts of frozen human corpus luteum

Aqueous extracts of frozen human corpora lutea were tested for the presence of an inhibitor of luteinizing hormone-receptor site binding (LHRBI) and for the subsequent effect on the stimulatory response of luteinizing hormone (LH) on progesterone synthesis by sheep ovarian cells. In the presence of human corpus luteum extract of normal menstrual cycle (30,000-g supernatant), the binding of 125I human chorionic gonadotrophin (hCG) to granulosa and luteal cells of sheep ovaries was markedly reduced, but the ability of rat testicular LH receptors to bind labelled hCG was less affected. However, extracts of corpora lutea of the first trimester of pregnancy appeared to be less inhibitory on the binding of LH/hCG to ovarian cells and had no effect on the binding of rat testicular cells compared to those of normal menstrual cycle. Addition of both extracts separately inhibited the LH-stimulated in vitro progesterone synthesis by granulosa cell cultures and by incubated sheep corpus luteum slices. These findings provide evidence for the presence of LHRBI in human corpus luteum.     

Ovarian FAM110C (family with sequence similarity 110C): induction during the periovulatory period and regulation of granulosa cell cycle kinetics in rats

FAM110C belongs to a family of proteins that regulates cell proliferation. In the present study, the spatiotemporal expression pattern of FAM110C and its potential role were examined during the periovulatory period. Immature female rats were injected with equine chorionic gonadotropin (eCG) followed by human chorionic gonadotropin (hCG) and ovaries or granulosa cells were collected at various times after hCG administration (n = 3/time point). Expression levels of Fam110c mRNA and protein were highly induced both in intact ovaries and granulosa cells at 8 to 12 h after hCG treatment. In situ hybridization analysis demonstrated Fam110c mRNA expression was induced in theca and granulosa cells at 4 h after hCG, primarily localized to granulosa cells at 8 h and 12 h, and decreased at 24 h after hCG. There was negligible Fam110c mRNA detected in newly forming corpora lutea. In rat granulosa cell cultures, hCG induced expression of Fam110c mRNA was inhibited by RU486, whereas NS398 and AG1478 had no effect, suggesting that Fam110c expression is regulated in part by the progesterone receptor pathway. Promoter activity analysis revealed that an Sp1 site was important for the induction of Fam110c expression by hCG. Overexpression of FAM110C promoted granulosa cells to arrest at the G(1) phase of the cell cycle but did not change progesterone levels. In summary, hCG induces Fam110c mRNA expression in granulosa cells by activation of an Sp1-binding site and the actions of progesterone. Our findings suggest that FAM110C may control granulosa cell differentiation into luteal cells by arresting cell cycle progression.     

Cellular localization of gelatinases and tissue inhibitors of metalloproteinases during follicular growth, ovulation, and early luteal formation in the rat

The matrix metalloproteinase (MMP) system consists of a proteolytic component, the metalloproteinases, and an associated class of tissue inhibitors of metalloproteinases (TIMPs). We investigated the cellular localization of the TIMPs and the gelatinase family of MMPs throughout the latter stages of follicular growth and during the periovulatory period. Immature female rats were injected with eCG, and ovaries were collected at the time of eCG administration (0 h) and at 6, 12, 24, or 36 h after eCG injection (i.e., follicular development group). A second group of animals (periovulatory) was injected with eCG followed by hCG 48 h later, and ovaries were collected at 0, 12, and 24 h after hCG. Ovaries were processed for the cellular localization of gelatinase or TIMP mRNA or gelatinolytic activity. Gelatinase mRNA (MMP-2 and MMP-9) was localized to the theca of developing follicles and to the stroma. Following a hCG stimulus, MMP-2 mRNA increased as the granulosa cells of preovulatory follicles underwent luteinization during formation of the corpus luteum (CL). MMP-9 mRNA remained predominantly in the theca during this period. In situ zymography for gelatinolytic activity demonstrated a pattern of activity that corresponded with the localization of MMP-2 and MMP-9 mRNA around developing follicles. Gelatinolytic activity was observed at the apex of preovulatory follicles and throughout the forming CL. The mRNA for TIMP-1, -2, and -3 was localized to the stroma and theca of developing follicles. TIMP-3 mRNA was present in the granulosa cells of certain follicles but was absent in granulosa cells of adjacent follicles. At 12 h after hCG, luteinizing granulosa cells expressed TIMP-1 and TIMP-3 mRNA, but TIMP-2 mRNA was at levels equivalent to the background. In the newly forming CL at 24 h after hCG administration, the luteal cells expressed TIMP-1, -2, and -3 mRNA, although the pattern of cellular expression was unique for each of the TIMPs. These findings demonstrate that the MMPs and TIMPs are in the cellular compartments appropriate for impacting the remodeling of the extracellular matrix as the follicle grows, ovulates, and forms the CL.     

Assessment of luteal rescue and desensitization of macaque corpus luteum brought about by human chorionic gonadotrophin and deglycosylated human chorionic gonadotrophin treatment

The objective of the current study was to investigate the mechanism by which the corpus luteum (CL) of the monkey undergoes desensitization to luteinizing hormone following exposure to increasing concentration of human chorionic gonadotrophin (hCG) as it occurs in pregnancy. Female bonnet monkeys were injected (im) increasing doses of hCG or dghCG beginning from day 6 or 12 of the luteal phase for either 10 or 4 or 2 days. The day of oestrogen surge was considered as day ‘0’ of luteal phase. Luteal cells obtained from CL of these animals were incubated with hCG (2 and 200 pg/ml) or dbcAMP (2.5,25 and 100 M) for 3h at 37°C and progesterone secreted was estimated. Corpora lutea of normal cycling monkeys on day 10/16/22 of the luteal phase were used as controls. In addition thein vivo response to CG and deglycosylated hCG (dghCG) was assessed by determining serum steroid profiles following their administration. hCG (from 15–90 IU) but not dghCG (15-90 IU) treatment in vivo significantly (P < 0.05) elevated serum progesterone and oestradiol levels. Serum progesterone, however, could not be maintained at a elevated level by continuous treatment with hCG (from day 6–15), the progesterone level declining beyond day 13 of luteal phase. Administering low doses of hCG (15-90 IU/day) from day 6–9 or high doses (600 IU/day) on days 8 and 9 of the luteal phase resulted in significant increase (about 10-fold over corresponding control P < 0.005) in the ability of luteal cells to synthesize progesterone (incubated controls) in vitro. The luteal cells of the treated animals responded to dbcAMP (P < 0.05) but not to hCC added in vitro. The in vitro response of luteal cells to added hCG was inhibited by 0,50 and 100% if the animals were injected with low (15-90 IU) or medium (100 IU) between day 6–9 of luteal phase and high (600 IU on day 8 and 9 of luteal phase) doses of dghCG respectively; such treatment had no effect on responsivity of the cells to dbcAMP. The luteal cell responsiveness to dbcAMP in vitro was also blocked if hCG was administered for 10 days beginning day 6 of the luteal phase. Though short term hCG treatment during late luteal phase (from days 12—15) had no effect on luteal function, 10 day treatment beginning day 12 of luteal phase resulted in regain ofin vitro responsiveness to both hCG (P < 0.05) and dbcAMP (P < 0.05) suggesting that luteal rescue can occur even at this late stage. In conclusion, desensitization of the CL to hCG appears to be governed by the dose/period for which it is exposed to hCG/dghCG. That desensitization is due to receptor occupancy is brought out by the fact that (i) this can be achieved by giving a larger dose of hCG over a 2 day period instead of a lower dose of the hormone for a longer (4 to 10 days) period and (ii) the effect can largely be reproduced by using dghCG instead of hCG to block the receptor sites. It appears that to achieve desensitization to dbcAMP also it is necessary to expose the luteal cell to relatively high dose of hCG for more than 4 days     

Trial of support treatment with human chorionic gonadotrophin in the luteal phase after treatment with buserelin and human menopausal gonadotrophin in women taking part in an in vitro fertilisation programme.

OBJECTIVE--To evaluate the effect of support with human chorionic gonadotrophin in the luteal phase in women taking part in an in vitro fertilisation programme after buserelin and human menopausal gonadotrophin were used to hyperstimulate their ovaries. DESIGN--Controlled group comparison. SETTING--Outpatient department of a private hospital. PATIENTS--115 Women with indications for in vitro fertilisation, all of whom had at least one embryo transferred. INTERVENTIONS--After suppression of the pituitary with buserelin the ovaries of all the women were stimulated with human menopausal gonadotrophin on day 4 of the luteal phase. Human chorionic gonadotrophin (10,000 IU) was given to induce ovulation, and oocytes were recovered 34 hours later. Embryos were transferred 46 to 48 hours after insemination. Women who had received the 10,000 IU of human chorionic gonadotrophin on a date that was an uneven number (n = 61) were allocated to receive support doses of 2500 IU human chorionic gonadotrophin three and six days after that date. The remaining 54 women did not receive hormonal support. END POINT--Determination of the rates of pregnancy. MEASUREMENTS and main results--Support with human chorionic gonadotrophin did not significantly alter the progesterone or oestradiol concentrations in the early or mid-luteal phase. The mean (range) progesterone concentrations in the late luteal phase in women who did not become pregnant were, however, significantly higher in those who received support (16(9-110) nmol/l nu 8(4-46) nmol/l), and the luteal phase was significantly longer in this group (14 days nu 12 days). The rate of pregnancy was significantly higher in the women who received support than in those who did not (25/61 nu 8/54). CONCLUSIONS--When buserelin and human menopausal gonadotrophin are used to hyperstimulate ovaries support with human chorionic gonadotrophin in the luteal phase has a beneficial effect on in vitro fertilisation.     

Expression and regulation of ang-2 in murine ovaries during sexual maturation and development of corpus luteum

The aim of this study was to examine the expression and regulation of angiopoietin-2 (Ang-2) in murine ovaries during sexual maturation, gonadotropin treatment and luteal development by in situ hybridization and RT-PCR. By in situ hybridization Ang-2 mRNA was mainly localized in granulosa cells, thecal cells and corpus luteum, otherwise in oocytes. Moreover, Ang-2 mRNA was highly expressed in corpus luteum and granulosa cells of atretic follicles. According to RT-PCR data, Ang-2 mRNA was lowly expressed on day 10 after birth, then expression levels gradually increased and reached their highest values on day 25 after birth. In the superovulated model of immature mice, Ang-2 expression was strongly induced by equine chorionic gonadotropin (eCG) 48 h post the eCG injection, and was high from 0.5 to 13 h after hCG treatment. in situ hybridization showed that Ang-2 mRNA was highly expressed in corpus luteum from day 2 to 9 post the hCG injection, then the expression levels gradually declined on days 11 and 13 after hCG treatment. According to RT-PCR data, the levels of Ang-2 mRNA expression showed a decline after the hCG injection, with a nadir on day 3, followed by an increase, reaching the highest level on day 9 post-hCG injection. Then again Ang-2 expression gradually declined from day 11 to 15 after hCG injection. These results suggest that Ang-2 may be involved in follicular development, atresia, ovulation, and corpus luteum formation and regression.     

The role of plasma lipoproteins in steroidogenic response of rat luteal cells during gonadotropin-induced refractory states

Administration of human chorionic gonadotropin (hCG) to pregnant mare's serum gonadotropin--hCG primed rats results in the loss of in vitro responsiveness of the ovaries to exogenous gonadotropins for progesterone production. This state is associated with a loss of membrane receptors for hCG and a concomitant increase in lipoprotein receptors. Although lipoproteins potentiated gonadotropin response in ovaries from saline-injected rats, no stimulation was observed in hCG-desensitized ovarian cells. Examination of the time course for the loss of lipoprotein response after hCG injection revealed that injection with 50 IU of hCG results in a loss of gonadotropin response as early as 1 h after injection, but exogenous cholesterol-carrying lipoprotein fractions, LDL and HDL, were capable of stimulating progesterone production up to 4 h after hormone injection. Measurement of endogenous cholesteryl ester content showed that there was a 72% decline during this period with a concomitant increase in the basal progesterone production. One hour after hCG injection there was no stimulation of steroidogenesis by hCG in the presence or absence of exogenous lipoproteins. The refractoriness to exogenous hCG appeared only 4 h later when the hCG dose was reduced to 10 IU, whereas with 25 IU of hCG, the effect was similar to that observed using 50 IU of hCG. Such diverse steroidogenic stimuli as hCG, LH, LDL, cAMP, and cholera enterotoxin failed to stimulate progesterone synthesis in vitro in luteal cells of rats injected with 50 IU of hCG 48 h prior to sacrifice.(ABSTRACT TRUNCATED AT 250 WORDS)